Earnshaw S, Brogan AJ, Brodtkorb TH, Davis AE. Budget impact analysis II: applications and design issues - virtual. Presentation to be given at the 2024 Virtual ISPOR Short Course Program; December 4, 2024. Previously presented at the 2015 ISPOR 20th Annual International Meeting.
Brogan AJ, Davis AE, Mellott CE, Fraysse J, Metzner AA, Oglesby AK. Cost-effectiveness of cabotegravir long-acting for HIV pre-exposure prophylaxis in the United States. Pharmacoeconomics. 2024 Apr;42(4):447-61. doi: 10.1007/s40273-023-01342-y
Brodtkorb T-H, Brogan A, Davis A, Earnshaw S. Budget impact analysis II: applications and design issues. Presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark. Previously presented at the 2022 Virtual ISPOR Short Course Program.
Bisanzio D, Davis AE, Talbird SE, Van Effelterre T, Metz L, Gaudig M, Mathieu VO, Brogan AJ. Targeted preventive vaccination campaigns to reduce Ebola outbreaks: an individual-based modeling study. Vaccine. 2022 Dec 14;S0264-410X(22):01449-9. doi: 10.1016/j.vaccine.2022.11.036
Earnshaw S, Brogan A, Brodtkorb TH, Davis AE. Budget impact analysis II: applications and design issues. Presented at the 2022 Virtual ISPOR Short Course Program; September 21, 2022. Previously presented at the 2021 Virtual ISPOR Short Course Program.
Oglesby A, Davis AE, Mellott CE, Fraysse J, Swygard H, Brogan A. Estimating the number of individuals needed to treat with different pre-exposure Prophylaxis options to avoid 1 new HIV-1 infection in the United States. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).
Davis A, Brogan A, Mellott CE, Fraysse J, Oglesby A. Cost-effectiveness of every two month Cabotegravir long-acting (CAB-LA) compared with daily oral Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) for pre-exposure Prophylaxis (PrEP) to prevent HIV-1 infection in the United States. Presented at the ISPOR 2022 Conference; May 10, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).
Earnshaw S, Brogan AJ, Brodtkorb T-H, Davis AE. Budget impact analysis II: applications and design issues. Presented at the 2021 Virtual ISPOR Short Course Program; December 6, 2021. Previously presented at the ISPOR 20th Annual International Meeting.
Bisanzio D, Davis AE, Talbird SE, Van Effelterre T, Metz L, Mathieu VO, Brogan AJ. Individual-based modeling of Ebola outbreaks in the DRC to assess the impact of preventive vaccination strategies. Poster presented at the 8th International Conference on Infectious Disease Dynamics; November 30, 2021. Bologna, Italy.
Brogan AJ, Talbird SE, Davis AE, La EM, Kumar PN. The cost-effectiveness and budget impact of ibalizumab-uiyk for adults with multidrug-resistant HIV-1 infection in the United States. Pharmacoeconomics. 2021 Apr;39(4):421-32. doi: 10.1007/s40273-020-00992-6
La EM, Talbird SE, Brogan AJ, Davis AE. Budget-impact analysis of ibalizumab in the treatment of US Medicare beneficiaries with multidrug-resistant HIV-1 infection. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S174. doi: 10.1016/j.jval.2020.04.371
Brogan AJ, Talbird SE, Davis AE, Wild L, Flanagan D. Is increased screening and early antiretroviral treatment for HIV-1 worth the investment? An analysis of the public health and economic impact of improvement in the UK. HIV Med. 2019 Nov;20(10):668-80. doi: 10.1111/hiv.12788
Davis A, Brogan AJ, Talbird S, Wild L, Flanagan D. The public health and economic impact of increased screening and immediate initiation of antiretroviral treatment for HIV-1 in the UK. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.
Earnshaw SR, Brogan AJ, Davis AE. Budget impact analysis II: applications & design issues. Presented at the 2018 ISPOR 21st Annual European Congress; November 11, 2018. Barcelona, Spain. Previously presented at the ISPOR 20th Annual International Meeting.
Brogan AJ, Davis AE, Goodwin B. Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States. PLoS One. 2018 Aug 30;13(8):e0203293. doi: 10.1371/journal.pone.0203293
Brogan AJ, Talbird SE, Davis AE, La EM, Miao Z, Lewis S. Long-term health benefit of ibalizumab in the treatment of adults with multidrug-resistant HIV-1 infection. Presented at the 2018 ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD.
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Brogan AJ, Talbird SE, Davis AE, Thommes EW, Meier G. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: a dynamic transmission modeling approach. Hum Vaccin Immunother. 2017 Mar 4;13(3):533-42. doi: 10.1080/21645515.2016.1242541
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Cost analysis of Raltegravir versus Atazanavir/r or Darunavir/r for treatment-naive adults with HIV-1 infection in Spain. Poster presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A410.
Davis AE, Brogan AJ, Goodwin BB. Cost analysis of raltegravir versus atazanavir/r or darunavir/r for treatment-naive adults with HIV-1 infection in the United States. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A214-5.